919 East Hillsdale Boulevard
Suite 250
Foster City, CA 94404
United States
650 473 7700
https://www.geron.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 141
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. John A. Scarlett M.D. | Chairman of the Board, President & CEO | 1.53M | N/A | 1951 |
Dr. Andrew J. Grethlein Ph.D. | Executive VP & COO | 847.2k | N/A | 1964 |
Ms. Michelle J. Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer | N/A | N/A | 1968 |
Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Mr. Scott Samuels | Executive VP, Chief Legal Officer & Corporate Secretary | N/A | N/A | N/A |
Ms. Shannon Odam | Senior VP & Chief People Officer | N/A | N/A | 1975 |
Ms. Melissa A. Kelly Behrs | Executive VP of Business Operations & Chief Alliance Officer | 753.22k | N/A | 1964 |
Mr. Anil Kapur | Executive VP of Corporate Strategy & Chief Commercial Officer | 654.89k | N/A | 1971 |
Mr. Edward E. Koval | Executive VP & Chief Business Officer | N/A | N/A | 1962 |
Dr. Faye Feller M.D. | Executive VP & Chief Medical Officer | N/A | N/A | 1983 |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation’s ISS Governance QualityScore as of March 1, 2024 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 9; Compensation: 6.